Table 3.
Criteria for progression used in AS protocol
| Protocol | Gleason | Positive Cores | Percentage of Core Affected | PSADT |
|---|---|---|---|---|
| Tosoian et al. (15) | >6 | >2 | >50 | — |
| Klotz et al. (16) | >4+3 | — | — | <3 |
| Dall'Era et al. (18) | Increase | — | — | — |
| Soloway et al. (21) | >3+3 | >2 | — | — |
| Thomsen et al. (63) | ≥4+3 | >3 | — | <3/5 |
Abbreviation: PSADT = prostate-specific antigen doubling time